The Justice et al. (2019) D+Q frailty trial randomized 29 individuals ≥70 years with walking limitations (physical frailty) to receive D+Q (dasatinib 100 mg + quercetin 1,000 mg × 3 days over 3 weeks) or placebo. The D+Q group showed significant improvements in 400m gait speed (primary endpoint, p=0.0001), 5x chair stand time (p=0.018), and SF-36 physical function domain (p=0.036).

Who qualifies as physically frail?

Fried Frailty Criteria include ≥3 of: unintentional weight loss, exhaustion, low physical activity, slow gait speed (<0.8 m/sec), and weak grip strength. Pre-frailty (1–2 criteria) is a target for preventive intervention.

Should older adults take senolytics to prevent frailty?

The frailty trial provides the strongest functional outcome evidence for D+Q. For prevention (before frailty develops), natural senolytics (fisetin, quercetin) represent a lower-risk starting point. Those already frail may benefit from physician-supervised D+Q.